Notices. Notice; reopening of the comment period
456 words·~2 min read·
/register/2011/12/21/2011-32565·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2011-N-0655] Animal Generic Drug User Fee Act; Reopening of the Comment Period AGENCY: Food and Drug Administration, HHS. ACTION: Notice; reopening of the comment period. SUMMARY: The Food and Drug Administration (FDA or Agency) is extending to January 15, 2013, the comment period for the notice of public meeting; request for public comments, published in the **Federal Register** of September 20, 2011 (76 FR 58277).
In that notice, FDA requested comments on the Animal Generic Drug User Fee Act (AGDUFA) program to date and solicited suggestions regarding the features FDA should propose for the next AGDUFA program. The Agency is taking this action to ensure that interested persons have the option of submitting comments throughout the reauthorization of AGDUFA. DATES: Submit either electronic or written comments by January 15, 2013. ADDRESSES: Submit electronic comments to: *http://www.regulations.gov.* Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Identify comments with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Donal Parks, Center for Veterinary Medicine (HFV-010), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855,
(240)276-8688, *AGDUFAReauthorization@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: I. Background In the **Federal Register** of September 20, 2011, FDA published a notice of public meeting; request for comments, to solicit input from the public on what FDA should consider including in the reauthorization of AGDUFA. FDA is interested in responses from the public on the following two general questions and welcomes other pertinent information that stakeholders would like to share: 1. What is your assessment of the overall performance of the AGDUFA program thus far? 2. What aspects of AGDUFA should be retained, changed, or discontinued to further strengthen and improve the program? Additional background materials, including the transcript of the public meeting, are available on the FDA's Web site. The Agency is reopening the comment period to allow members of the general public or of stakeholder groups the opportunity to provide comments throughout the process of reauthorizing AGDUFA. II. How to Submit Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES ) either electronic or written comments on this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Dated: December 15, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011-32565 Filed 12-20-11; 8:45 am]